Spots Global Cancer Trial Database for trastuzumab deruxtecan
Every month we try and update this database with for trastuzumab deruxtecan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) | NCT06210776 | HER2-positive B... HER2-low Breast... Breast Cancer Advanced Cancer | Trastuzumab der... | 18 Years - | Daiichi Sankyo | |
| DESTINY Breast Respond HER2-low Europe | NCT05945732 | Unresectable Br... Metastatic Brea... HER2-low Expres... | Trastuzumab der... | 18 Years - | Daiichi Sankyo | |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | NCT03742102 | Triple Negative... | Durvalumab Capivasertib Oleclumab Paclitaxel Trastuzumab der... Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| TRUDI: TDXD+Durva in HER2+/Low IBC | NCT05795101 | Invasive Breast... Inflammatory Br... HER2-positive B... HER2 Low Breast... Breast Cancer | Trastuzumab der... Durvalumab | 18 Years - | Dana-Farber Cancer Institute | |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | NCT04379596 | Gastric Cancer | Fluorouracil (5... Capecitabine Durvalumab Oxaliplatin Trastuzumab Trastuzumab der... Cisplatin Pembrolizumab Volrustomig Rilvegostomig | 18 Years - 130 Years | AstraZeneca | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients | NCT05953168 | Triple-Negative... | Trastuzumab Der... | 18 Years - 70 Years | Fudan University | |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | NCT04704661 | Advanced Breast... Advanced Colon ... Advanced Colore... Advanced Endome... Advanced Gastri... Advanced Gastro... Advanced Malign... Advanced Saliva... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... HER2-Positive B... Malignant Hepat... Metastatic Brea... Metastatic Gast... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Colon... Stage III Color... Stage III Major... Stage III Uteri... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Uter... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Colon ... Stage IV Colore... Stage IV Major ... Stage IV Uterin... Stage IVA Colon... Stage IVA Color... Stage IVA Major... Stage IVA Uteri... Stage IVB Colon... Stage IVB Color... Stage IVB Major... Stage IVB Uteri... Stage IVC Colon... Stage IVC Color... Stage IVC Major... Unresectable Co... Unresectable Ga... Unresectable Ma... | Ceralasertib Trastuzumab Der... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | NCT05113251 | Breast Neoplasm... Breast Cancer HER2-positive E... | Trastuzumab Der... Paclitaxel Trastuzumab Pertuzumab Doxorubicin cyclophosphamid... | 18 Years - | AstraZeneca | |
| A Study of T-DXd in Patients With Selected HER2-overexpressing Tumors | NCT06271837 | Advanced Solid ... | Trastuzumab der... | 18 Years - 130 Years | AstraZeneca | |
| T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients | NCT05953168 | Triple-Negative... | Trastuzumab Der... | 18 Years - 70 Years | Fudan University | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| A PROSPECTIVE, MULTI-CENTER, PHASE 4 STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN | NCT06429761 | BREAST CANCER | Trastuzumab der... | 18 Years - | AstraZeneca | |
| Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | NCT04784715 | Breast Cancer; ... | Trastuzumab der... Placebo Taxane Pertuzumab Trastuzumab | 18 Years - 130 Years | AstraZeneca | |
| Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | NCT06058988 | Brain Cancer Glioblastoma Metastatic Canc... Leptomeningeal ... Recurrent Gliob... | Trastuzumab der... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | NCT05091528 | HER2-positive B... HER2-positive G... HER2-positive C... HER2-expressing... | SBT6050 trastuzumab der... tucatinib trastuzumab capecitabine trastuzumab der... | 18 Years - | Silverback Therapeutics | |
| A PROSPECTIVE, MULTI-CENTER, PHASE 4 STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN | NCT06429761 | BREAST CANCER | Trastuzumab der... | 18 Years - | AstraZeneca | |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | NCT06324357 | Metastatic Brea... Metastatic Gast... Gastroesophagea... Esophageal Aden... | Zongertinib Trastuzumab der... Trastuzumab emt... | 18 Years - | Boehringer Ingelheim | |
| EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan | NCT05458401 | HER2-positive B... | Trastuzumab der... | 18 Years - | Daiichi Sankyo | |
| EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan | NCT05458401 | HER2-positive B... | Trastuzumab der... | 18 Years - | Daiichi Sankyo | |
| HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer | NCT06328387 | Advanced Breast... Metastatic Brea... | Hydroxychloroqu... Sacituzumab Gov... Trastuzumab Der... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients | NCT05953168 | Triple-Negative... | Trastuzumab Der... | 18 Years - 70 Years | Fudan University | |
| DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | NCT03523585 | Breast Cancer | Trastuzumab der... Capecitabine Lapatinib Trastuzumab | 18 Years - | Daiichi Sankyo | |
| DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) | NCT04014075 | Adenocarcinoma ... Adenocarcinoma ... | Trastuzumab der... | 18 Years - | Daiichi Sankyo | |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | NCT04553770 | Early-stage Bre... Hormone Recepto... Invasive Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... | Anastrozole Therapeutic Con... Trastuzumab Der... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer | NCT05594082 | Breast Cancer | Trastuzumab Der... | 18 Years - | Fudan University | |
| DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease | NCT04420598 | Advanced Breast... HER2-positive B... Brain Metastase... Leptomeningeal ... | Trastuzumab der... | 18 Years - | MedSIR | |
| Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | NCT06409390 | Metastatic Brea... | Taxotere Cytoxan Trastuzumab der... Sacituzumab gov... Xeloda Fulvestrant Ribociclib Abemaciclib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer | NCT04556773 | Metastatic Brea... | Trastuzumab der... Durvalumab Paclitaxel Capivasertib Anastrozole Fulvestrant Capecitabine | 18 Years - | AstraZeneca | |
| A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | NCT04622319 | HER2-Positive P... Residual Invasi... | DS-8201a T-DM1 | 18 Years - | Daiichi Sankyo | |
| Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | NCT05950945 | Breast Cancer | Trastuzumab Der... | 18 Years - | Daiichi Sankyo | |
| A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) | NCT03248492 | Breast Cancer | DS-8201a | 18 Years - | Daiichi Sankyo | |
| A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer | NCT04538742 | Metastatic Brea... | Trastuzumab der... Durvalumab Paclitaxel Pertuzumab Tucatinib | 18 Years - | AstraZeneca | |
| A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | NCT05048797 | Locally Advance... | Trastuzumab Der... Cisplatin Carboplatin Pembrolizumab Pemetrexed | 18 Years - 123 Years | AstraZeneca | |
| Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer | NCT04294628 | Advanced Malign... HER2-Positive B... Metastatic Mali... Refractory Mali... Unresectable Ma... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab | NCT05744375 | Locally Advance... Metastatic Brea... | Trastuzumab der... | 18 Years - | Spanish Breast Cancer Research Group | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases | NCT06250777 | Non Small Cell ... | Trastuzumab der... | 20 Years - | Yonsei University | |
| Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC | NCT04686305 | Locally Advance... | T-DXd Durvalumab Cisplatin Carboplatin Pemetrexed MEDI5752 | 18 Years - | AstraZeneca | |
| HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer | NCT06328387 | Advanced Breast... Metastatic Brea... | Hydroxychloroqu... Sacituzumab Gov... Trastuzumab Der... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases | NCT04752059 | Breast Cancer S... | Trastuzumab der... | 18 Years - 100 Years | Medical University of Vienna | |
| Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases | NCT06250777 | Non Small Cell ... | Trastuzumab der... | 20 Years - | Yonsei University | |
| Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer | NCT04585958 | Endometrial Ser... Metastatic Mali... Unresectable Ma... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Olaparib Trastuzumab Der... | 18 Years - | National Cancer Institute (NCI) | |
| NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer | NCT05704829 | HER2-positive E... | Trastuzumab der... Standard-of-Car... | 18 Years - | West German Study Group | |
| DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer | NCT03505710 | Non-Small Cell ... | Trastuzumab der... | 18 Years - | Daiichi Sankyo | |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | NCT04553770 | Early-stage Bre... Hormone Recepto... Invasive Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... | Anastrozole Therapeutic Con... Trastuzumab Der... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer | NCT04585958 | Endometrial Ser... Metastatic Mali... Unresectable Ma... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Olaparib Trastuzumab Der... | 18 Years - | National Cancer Institute (NCI) | |
| Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer | NCT06331169 | Breast Cancer | Anlotinib Trastuzumab der... | 18 Years - 75 Years | Fudan University | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | NCT06439693 | Breast Cancer F... Breast Cancer Breast Cancer M... Estrogen Recept... HER2-positive B... Stage IV Breast... | Nab-Paclitaxel Paclitaxel Docetaxel Phesgo T-DM1 Pertuzumab Trastuzumab Der... Trastuzumab Sub... Tucatinib Trastuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | NCT04553770 | Early-stage Bre... Hormone Recepto... Invasive Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... | Anastrozole Therapeutic Con... Trastuzumab Der... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer | NCT05633979 | Breast Cancer | Trastuzumab der... Valemetostat | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations | NCT04639219 | Advanced Solid ... | Trastuzumab der... | 18 Years - 120 Years | AstraZeneca | |
| Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer | NCT05633979 | Breast Cancer | Trastuzumab der... Valemetostat | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer | NCT04294628 | Advanced Malign... HER2-Positive B... Metastatic Mali... Refractory Mali... Unresectable Ma... | Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer | NCT04494425 | Advanced or Met... | Trastuzumab der... Capecitabine Paclitaxel Nab-Paclitaxel | 18 Years - 105 Years | AstraZeneca | |
| A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer | NCT04739761 | Breast Cancer | Trastuzumab Der... | 18 Years - 130 Years | AstraZeneca | |
| A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer | NCT04539938 | HER2 Positive B... | tucatinib trastuzumab der... | 18 Years - | Seagen Inc. | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | NCT06409390 | Metastatic Brea... | Taxotere Cytoxan Trastuzumab der... Sacituzumab gov... Xeloda Fulvestrant Ribociclib Abemaciclib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| TRUDI: TDXD+Durva in HER2+/Low IBC | NCT05795101 | Invasive Breast... Inflammatory Br... HER2-positive B... HER2 Low Breast... Breast Cancer | Trastuzumab der... Durvalumab | 18 Years - | Dana-Farber Cancer Institute | |
| Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil | NCT06231693 | Breast Cancer | Trastuzumab der... | 18 Years - | AstraZeneca | |
| Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | NCT04704934 | Gastric Cancer,... Gastroesophagea... | Trastuzumab der... Ramucirumab Paclitaxel | 18 Years - | Daiichi Sankyo | |
| Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) | NCT04644237 | Non-Small Cell ... | Trastuzumab der... | 18 Years - | Daiichi Sankyo | |
| A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer | NCT04739761 | Breast Cancer | Trastuzumab Der... | 18 Years - 130 Years | AstraZeneca | |
| Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma | NCT04616560 | Osteosarcoma Recurrent Osteo... | Trastuzumab Der... | 12 Years - 39 Years | National Cancer Institute (NCI) | |
| PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer | NCT06172127 | HER2-positive B... | Trastuzumab der... Phesgo 1,200 MG... Phesgo 600 MG /... | 18 Years - | MedSIR | |
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors | NCT06364410 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Mali... Unresectable Ga... Unresectable Ga... Unresectable Ma... | Azenosertib Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer | NCT04539938 | HER2 Positive B... | tucatinib trastuzumab der... | 18 Years - | Seagen Inc. | |
| Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors | NCT06364410 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Mali... Unresectable Ga... Unresectable Ga... Unresectable Ma... | Azenosertib Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer | NCT04494425 | Advanced or Met... | Trastuzumab der... Capecitabine Paclitaxel Nab-Paclitaxel | 18 Years - 105 Years | AstraZeneca | |
| Basket Study for Oligo-metastatic Breast Cancer | NCT05982678 | HER2-positive B... | Trastuzumab der... | 18 Years - | The Netherlands Cancer Institute | |
| Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer | NCT03523572 | Breast Cancer Urothelial Carc... | Trastuzumab der... Nivolumab | 18 Years - | Daiichi Sankyo | |
| An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis | NCT05376878 | Anatomic Stage ... Metastatic Brea... Metastatic Mali... | Copper Cu 64-DO... Magnetic Resona... Positron Emissi... Trastuzumab Trastuzumab Der... | 18 Years - | City of Hope Medical Center | |
| Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer | NCT05900206 | Breast Cancer | Trastuzumab der... Docetaxel Paclitaxel Carboplatin Trastuzumab Pertuzumab Ribociclib Letrozole Epirubicin Cyclophosphamid... | 18 Years - | Karolinska University Hospital | |
| The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | NCT06439693 | Breast Cancer F... Breast Cancer Breast Cancer M... Estrogen Recept... HER2-positive B... Stage IV Breast... | Nab-Paclitaxel Paclitaxel Docetaxel Phesgo T-DM1 Pertuzumab Trastuzumab Der... Trastuzumab Sub... Tucatinib Trastuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | NCT04379596 | Gastric Cancer | Fluorouracil (5... Capecitabine Durvalumab Oxaliplatin Trastuzumab Trastuzumab der... Cisplatin Pembrolizumab Volrustomig Rilvegostomig | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
